Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
The viability of MIA PaCa-2 cells is inhibited by oxythiamine (0–40 μM, 2 days) (IC50: 14.95 μM)[1]. MIA PaCa-2 cells' ability to proliferate is inhibited by oxythiamine (0-500 μM, 48 hours) (IC50: 14.95 μM)[1]. The proliferation of A549 cells is inhibited by oxythiamine (0.1-100 μM, 6-48 h) [3]. 3 expression of protein/α [1]. A549 cell adapters are sensed by oxythiamine (0.1-100 μM, 24 h) [3]. Lewis lung cancer (LLC) cell minimization and migration are inhibited by oxythiamine (0–20 μM) (IC50: 8.75 μM) [4].
|
---|---|
ln Vivo |
In mice with Ehrlich ascites tumors, oxythiamine (100–500 mg/kg, intraperitoneally for 4 days) reduces the formation of tumors [2]. For five weeks, oxythiamine (250 or 500 mg/kg once daily) was administered via inhibition ring.
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: MIA PaCa-2 cells Tested Concentrations: 0-40 μM Incubation Duration: 2 days Experimental Results: Inhibits cell viability, IC50 is 14.95 μM. Western Blot Analysis [1] Cell Types: MIA PaCa-2 cells Tested Concentrations: 0, 5, 50, 500 μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibited 14-3-3 protein β/α expression and increased α-enolase . |
Animal Protocol |
Animal/Disease Models: Ehrlich ascites tumor host mouse [2]
Doses: 100-500 mg/kg Route of Administration: intraperitoneal (ip) injection, 4-day Experimental Results: Inhibition of tumor growth was 43% at 300 mg/kg and 84% at 500 mg/kg. |
References |
[1]. Wang J, et al. Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Exp Hematol Oncol. 2013 Jul 27;2:18.
[2]. Raïs B, et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle. FEBS Lett. 1999 Jul 30;456(1):113-8. [3]. Bai L, et al. A dose- and time-dependent effect of oxythiamine on cell growth inhibition in non-small cell lung cancer. Cogn Neurodyn. 2022 Jun;16(3):633-641. [4]. Yang CM, et al. The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action. Clin Exp Metastasis. 2010 May;27(5):341-9. |
Molecular Formula |
C12H16N3O2S+.CL-
|
---|---|
Molecular Weight |
301.79234
|
CAS # |
136-16-3
|
Related CAS # |
Oxythiamine chloride hydrochloride;614-05-1
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
CC1=C(CCO)SC=[N+]1CC2=CN=C(C)NC2=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~51.67 mg/mL (~194.00 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.58 mg/mL (9.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.58 mg/mL (9.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.58 mg/mL (9.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.3136 mL | 16.5678 mL | 33.1356 mL | |
5 mM | 0.6627 mL | 3.3136 mL | 6.6271 mL | |
10 mM | 0.3314 mL | 1.6568 mL | 3.3136 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.